Posters and Abstracts
July 2025
Long-Acting Injectable Dose Prediction: Where Are We Really?
Seda Author(s) A. Mitchinson, J. Dickinson, L. Ruston, C. Patterson, P.A. Dickinson
Date: July 2025
Published: CRS 2025 / Philadelphia
April 2025
Translational PK/PD Modelling of MEK inhibitors: Trametinib, Cobimetinib and Binimetinib
Seda Author(s) J. Dickinson
Date: April 2025
Published: AACR Chicago 2025
Nov 2024
Harnessing GitLab, R and LaTeX to perform bespoke and robust non-compartmental analysis for patient SAD and MAD studies
Seda Author(s) E. Fell, A. Wilby, J. Dickinson, P. Dickinson, H. Dickinson
Date: Nov 2024
Published: PKUK 2024/ Bracknell / UK
June 2024
Investigating the influence of manufacturing process of lipid-based formulations on intracellular delivery of siRNA
Seda Author(s) C. Patterson
Date: June 2024
Published: ETPN 2024 / Milam
December 2023
Model Informed-Development of Amorphous Systems (MI-DAS) – an in-silico polymer selection tool for ASD development
Seda Author(s) E. Roberts, H. Dickinson, T. Austin, S. Budhdeo, M. de Matas, P. Stott
Date: December 2023
Published: British Journal of Pharmacy
Oct 2022
Setting up success in the clinic through semi-mechanistic translational modelling
Seda Author(s) J. Dickinson
Date: Oct 2022
Published: AAPS PharmSci 360, Boston
July 2022
Population PK modelling as an alternative route to bioequivalence
Seda Author(s) J. Dickinson, H. Dickinson, L. Ruston, C. Patterson, P.A. Dickinson
Date: July 2022
Published: British Journal of Pharmacy
April 2022
Development of a methodology to enable non-linear in vitro-in vivo correlation for complex long-acting injections
Seda Author(s) J. Dickinson, C. Patterson, P.A. Dickinson
Date: April 2022
Published: Quantitative Systems Pharmacology Conference 2022
September 2021
First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies
Seda Author(s) P.A. Dickinson
Date: September 2021
Published: OncologyPRO
September 2021
Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)
Seda Author(s) P.A. Dickinson
Date: September 2021
Published: OncologyPRO
September 2021
Evaluation of In-situ UV Fibre Optic Arch Probe vs. traditional offline LC-UV analysis for ‘real-world’ dissolution studies
Seda Author(s) H. Dickinson, P.A. Dickinson, C. Patterson
Date: September 2021
Published: Virtual APS PharmSci 2021
September 2021
Development of a methodology to enable non-linear in vitro-in vivo correlation for complex long-acting injections
Seda Author(s) J. Dickinson, C. Patterson, P. Gajjar, P.A. Dickinson
Date: September 2021
Published: AAPS PharmSci 360